Most Recent
Kicking off its appeal of a finding that it couldn't walk away from a $672 million merger agreement with Mayne Pharma, US drug company Cosette has told a court that Mayne was not upfront about its financial position prior to the deal.
US drug maker Cosette is appealing a judge’s decision not to disqualify himself from Mayne Pharma's lawsuit seeking damages over the termination of their $672 million if he is appointed to case manage the dispute.
A union representing medical officers has lost its appeal of a ruling which found that junior doctors at state-run hospitals in NSW are not temporary employees who are entitled to a 10 per cent allowance.
Construction PRO
Rejecting Victoria's bid for a quick win in a case by Pakenham Place Shopping Centre over the development of a new hospital in Melbourne's southeast, a judge has warned against "last-resort" summary dismissal applications.
AstraZeneca has slammed Pharmacor's defence to claims it infringed a patent for blockbuster diabetes drug Forxiga as a "complete shot in the dark", as the drug maker unsuccessfully fought orders to produce documents from a UK case.
It ditched a planned $627 million union, now US drug maker Cosette must pay more than $13 million toward Mayne Pharma's costs of the legal fallout. Whether it owes the "substantial damages" Mayne is claiming is an issue for another day.
Cosmetic surgeon Dr Daniel Lanzer wants to strip a case of class action status, arguing claims he and other doctors passed themselves off as plastic surgeons were not suitable for a group proceeding.
Sydney's St Vincent’s Hospital says the doctor leading a class action over alleged unpaid overtime can't bring the case because she did not file overtime claims.
Mayne Pharma cannot access invoices from Cosette’s solicitors at Corrs Chambers Westgarth, with a judge saying he was not hopeful that they would help to resolve a costs fight related to litigation over their collapsed $672 million merger.
Trial in AstraZeneca's patent infringement case over Pharmacor's plans to launch a cheaper version of diabetes drug Forxiga has been delayed to October, after the generic drug maker got the all-clear to revise its cross-claim.